Know More About “Nordic Regulatory Affairs Market 2021-2028” Growth Worldwide…

Posted by Mrudula Anil Karmarkar on March 3rd, 2022

The Nordic regulatory affairs market size is expected to reach USD 272.7 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.5% from 2021 to 2028. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market.

Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for a faster drug approval process is one of the key factors expected to drive the market in the country.

In Sweden, as stated by the SwedenBIO, around 148 companies have 420 drug development projects; an increase by 51 projects compared to 2016. In addition, around 6% of the total exports from Sweden are related to pharmaceuticals. Hence, this is projected to create demand for regulatory affairs services in the country.

The ongoing COVID-19 pandemic is expected to create the need for regulatory affairs in the Nordic countries. Countries such as Sweden and Denmark, which are the hub of clinical trials, are expected to witness an increase in demand for regulatory services as many of the trials are put on hold. In addition to this, due to COVID-19, a significant number of vaccines and drugs are in the development stage, which requires faster approval. This is possible only through clearance by regulatory bodies. Thus, the need for regulatory affairs is expected to increase in the Nordic countries.

Changing regulatory landscape, increasing demand for the faster approval process, and economic and competitive pressures are some of the key factors expected to drive the market. The entry of life sciences companies in the Nordic markets, especially in countries such as Denmark and Sweden, for R&D collaborations and the evolution of new areas, such as orphan drugs, biosimilars, advanced therapy medicinal products (ATMPs), and personalized medicine, are further anticipated to contribute to the market growth. This is because new areas would require advanced technical expertise for compliance with regulatory requirements.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/nordic-regulatory-affairs-market/request/rs1

Nordic Regulatory Affairs Market Report Highlights

• By service, the regulatory writing and publishing segment led the market in 2020 owing to an increase in the outsourcing of selected regulatory functions by major life sciences companies
• Based on category, the medical devices segment held the largest share in 2020. The segment is driven by stiff competition owing to the increased demand for wearable devices
• Sweden dominated the market with a share of 59.6% in 2020 due to a rise in the number of drug development projects
• Changing regulatory landscape, increasing need for companies to focus on core business activities, and economic and competitive pressures are the main factors responsible for the market growth

Companies provide various services such as regulatory consulting and writing and publishing for various pharmaceutical and medical devices companies. In January 2020, ICON Investments Limited acquired MedPass International, which has a significant presence in the European region as a regulatory and reimbursement consultant. The core competencies of MedPass are in market access and medical device development (class III).

Some prominent players in the Nordic regulatory affairs market include:

• Pharma Assist Sweden AB
• GenPact Ltd.
• ICON plc
• Freyr
• Global Pharma Consultancy AB
• Regsmart Lifesciences AB
• PRA Health Sciences
• Charles River Laboratories International, Inc.
• Parexel International Corporation, Inc.
• Accell Clinical Research LLC